Epobis 10mg vial

10 mg vial · Batch No.010

Epobis: Benefits, Mechanism, Safety & Research Review

Epobis is an experimental erythropoietin receptor (EPOR) agonist peptide derived from a receptor-binding region of human erythropoietin (EPO).

Its peptide sequence is:

Asn-Glu-Asn-Ile-Thr-Val-Pro-Asp-Thr-Lys-Val-Asn-Phe-Tyr-Ala-Trp-Lys-Arg

or:

NENITVPDTKVNFYAWKR

The linear 18-amino-acid peptide is listed with CAS number 915091-83-7, molecular formula C₁₀₀H₁₅₁N₂₇O₂₉, and molecular weight approximately 2195.44 g/mol.

Importantly, the principal published Epobis experiments used a tetrameric/dendrimeric version of the peptide, designed to activate the erythropoietin receptor without producing the strong erythropoietic activity associated with EPO itself.

Preclinical studies suggest Epobis may promote neurite growth, neuronal survival, anti-inflammatory signaling and memory-related effects, while remaining nonerythropoietic under the experimental conditions studied.

1. Potential Benefits of Epobis

Benefit	Key take-away
1. Neuroprotection	Epobis increased neuronal survival in experimental cell models.
2. Neurite growth	Promoted neuritogenesis in several primary neuronal cultures.
3. EPOR activation	Specifically binds the erythropoietin receptor and activates downstream signaling.
4. Anti-inflammatory activity	Reduced TNF release from activated macrophages and microglia.
5. Memory research	Improved delayed social-recognition memory in rats in one preclinical study.
6. Blood-brain barrier penetration	Systemically administered Epobis was detected in cerebrospinal fluid in rats.
7. Neuroregeneration research	Neurite-promoting activity makes Epobis relevant to neuronal repair research.
8. EAE research	Delayed clinical signs in an experimental autoimmune encephalomyelitis model.
9. STAT5 signaling	EPOR activation by Epobis is associated with STAT5 signaling.
10. Nonerythropoietic EPOR signaling	Produced neurobiological effects without significant hematopoietic stimulation in studied animal models.

2. Epobis Mechanism of Action

2.1 Erythropoietin Receptor Activation

The principal mechanism of Epobis is agonism of the erythropoietin receptor (EPOR).

Erythropoietin normally activates EPOR to regulate red-blood-cell production, but EPOR is also expressed in several nonhematopoietic tissues, including the nervous system.

Epobis was designed from an EPO receptor-binding sequence and specifically binds EPOR.

Surface-plasmon-resonance experiments reported an apparent binding affinity of approximately 60 nM, while neuronal experiments showed EPOR-dependent neurite growth and survival.

A simplified model is:

Epobis → EPOR activation → intracellular signaling → neuronal survival + neurite growth + tissue-protective signaling

2.2 Proposed Downstream Biology

Pathway	Functional outcome	Context
EPOR activation	Receptor signaling	Neuroprotection
STAT5 activation	Gene transcription	Cell survival
Neuritogenesis ↑	Increased neurite growth	Neuroregeneration
Neuronal survival ↑	Reduced experimental cell death	Neuroprotection
TNF release ↓	Reduced inflammatory signaling	Microglia / macrophages
CNS exposure	Peptide detected in CSF	Brain-related research

Epobis therefore attempts to separate the tissue-protective effects of EPO signaling from EPO’s powerful effects on red-blood-cell production.

3. Neuroprotection and Neuronal Survival

Neuroprotection is one of the strongest areas of Epobis research.

The original 2012 study found that Epobis promoted survival of hippocampal and cerebellar neurons exposed to experimental injury conditions.

It also induced neurite outgrowth in an EPOR-dependent manner.

These findings suggest that Epobis can activate neuronal survival pathways associated with erythropoietin signaling.

However, these experiments were primarily performed in cell cultures rather than humans.

4. Neuritogenesis and Neuroregeneration

Epobis has demonstrated particularly interesting effects on neurite outgrowth.

Neurites are projections from developing or regenerating neurons that can become axons or dendrites.

In experimental neuronal cultures, Epobis promoted neurite growth in:

• motoneurons,
• hippocampal neurons,
• cerebellar neurons.

The response was dose-dependent and associated with EPOR activation.

This makes Epobis scientifically interesting for research involving neuronal plasticity and neuroregeneration.

5. Anti-Inflammatory Effects

Epobis has also demonstrated anti-inflammatory activity.

In vitro experiments found that Epobis reduced tumor necrosis factor (TNF) release from activated:

• macrophages,
• primary microglia.

Microglia are the principal resident immune cells of the central nervous system.

The anti-inflammatory effect was broadly similar in direction to EPO, although Epobis was less potent under the experimental conditions.

This suggests:

Epobis → EPOR-related signaling → inflammatory cytokine modulation → reduced TNF release

6. Blood-Brain Barrier Penetration

One particularly important finding is that systemically administered Epobis was detectable in cerebrospinal fluid (CSF).

In rats, researchers reported a plasma-to-CSF ratio of approximately 20:1 two hours after systemic administration.

This provides experimental evidence that the studied Epobis preparation can reach the central nervous system.

However, this does not establish human brain bioavailability or pharmacokinetics.

7. Epobis and Memory

Epobis has also been investigated for possible effects on memory.

In rats, Epobis did not produce an immediate improvement in short-term social-recognition memory.

However, animals showed improved memory performance approximately three days after administration, suggesting a delayed or persistent neurobiological effect.

The authors interpreted this as evidence of a longer-term memory-enhancing effect.

There are currently no controlled human studies demonstrating cognitive enhancement from Epobis.

8. Epobis and Experimental Autoimmune Encephalomyelitis

Epobis has been evaluated in experimental autoimmune encephalomyelitis (EAE), a commonly used animal model for inflammatory demyelinating disease.

Systemic administration delayed the appearance of clinical disease signs.

However, Epobis did not completely prevent disease progression.

This suggests potential anti-inflammatory or neuroprotective activity rather than evidence that Epobis treats multiple sclerosis.

Human efficacy remains unknown.

9. Epobis Pharmacokinetics

The pharmacokinetics of Epobis are only partially characterized.

Available animal studies demonstrate that after systemic administration:

• Epobis is detectable in plasma,
• Epobis reaches cerebrospinal fluid,
• CNS exposure occurs within hours.

However, major parameters remain poorly defined, including:

• elimination half-life,
• Tmax,
• Cmax,
• absolute bioavailability,
• metabolic pathways,
• tissue distribution,
• human pharmacokinetics.

The existing research therefore provides evidence of CNS accessibility, but not a complete pharmacokinetic profile.

10. Epobis Safety and Tolerability

Nonerythropoietic Activity

A major objective behind Epobis development was to retain beneficial EPO-like signaling without strongly stimulating erythropoiesis.

In animal experiments, even longer-term Epobis administration did not produce the hematopoietic effects characteristic of EPO.

This is particularly important because excessive erythropoietic stimulation can increase:

• hematocrit,
• blood viscosity,
• thrombotic risk.

Important Safety Limitations

Epobis remains an experimental peptide.

Important unknowns include:

• long-term human safety,
• cardiovascular effects,
• immune effects,
• chronic EPOR activation,
• hepatic effects,
• renal effects,
• reproductive toxicity,
• pregnancy safety,
• drug interactions,
• carcinogenic potential.

No established human safety profile currently exists.

11. Epobis vs Erythropoietin (EPO)

Feature	Epobis	Erythropoietin
Main target	EPOR	EPOR
Structure	EPO-derived peptide	Full glycoprotein hormone
Neuroprotective research	Yes, preclinical	Yes
Neuritogenesis	Yes	Yes
Anti-inflammatory effects	Yes, preclinical	Yes
Blood-brain barrier exposure	Demonstrated in animals	Limited / context-dependent
Erythropoietic activity	Minimal / absent in studied models	Strong
Human clinical evidence	None established	Extensive
Approved medicine	No	Yes, for specific indications

The scientific interest in Epobis therefore comes from its attempt to produce EPOR-mediated tissue-protective signaling without strong erythropoiesis.

12. Evidence Profile

Claim	Evidence strength
Epobis binds EPOR	Strong mechanistic evidence
Epobis activates EPOR-related signaling	Strong preclinical evidence
Epobis promotes neurite growth	Strong preclinical evidence
Epobis promotes neuronal survival	Strong preclinical evidence
Epobis reduces TNF release	Preclinical evidence
Epobis crosses the BBB	Animal evidence
Epobis improves delayed memory	Animal evidence
Epobis delays EAE symptoms	Animal evidence
Epobis lacks major erythropoietic activity	Animal evidence
Epobis improves cognition in humans	Unknown
Epobis treats neurodegenerative disease	Unknown
Epobis treats multiple sclerosis	Unknown
Long-term human safety	Unknown

13. Regulatory and Research Status

• Name: Epobis
• Sequence: NENITVPDTKVNFYAWKR
• Length: 18 amino acids
• CAS number: 915091-83-7
• Molecular formula: C₁₀₀H₁₅₁N₂₇O₂₉
• Molecular weight: approximately 2195.44 g/mol
• Target: Erythropoietin receptor (EPOR)
• Compound class: EPO-derived experimental peptide
• Research area: Neuroprotection, neuroregeneration and inflammation
• Clinical stage: Preclinical
• Approved medicine: No

The principal academic studies used tetrameric/dendrimeric Epobis, whereas commercially listed linear Epobis corresponds to the 18-amino-acid sequence above. These preparations should not automatically be assumed to have identical biological activity.

14. Future Research

Future Epobis studies need to establish:

• full pharmacokinetics,
• biological half-life,
• human CNS penetration,
• optimal molecular format,
• monomer versus tetramer activity,
• dose-response relationships,
• receptor selectivity,
• duration of EPOR activation,
• cognitive effects,
• neuroprotective efficacy,
• inflammatory effects,
• cardiovascular safety,
• long-term toxicity,
• human safety.

Human clinical studies would be particularly important because current evidence is almost entirely cellular and animal-based.

15. Overall Evidence Assessment

Epobis is an unusual experimental neuroprotective peptide because it directly targets the erythropoietin receptor while attempting to avoid the hematopoietic effects of erythropoietin itself.

Its strongest evidence comes from mechanistic, cell-culture and animal studies.

Best-supported findings

• Epobis binds the erythropoietin receptor
• EPOR activation promotes downstream STAT5 signaling
• Epobis stimulates neurite outgrowth
• Epobis promotes neuronal survival
• Epobis reduces TNF release in inflammatory cell models
• Systemic Epobis reaches cerebrospinal fluid in rats
• Epobis delayed disease signs in an EAE animal model
• Epobis improved delayed social-recognition memory in rats
• Significant erythropoietic activity was not observed in studied animal models

Claims that remain uncertain

• Cognitive enhancement in humans
• Human neuroprotective efficacy
• Treatment of neurodegenerative disease
• Effects in multiple sclerosis
• Long-term human safety
• Optimal dose and exposure
• Human half-life
• Long-term cardiovascular safety
• Activity of linear versus dendrimeric Epobis

Overall: Epobis is an experimental nonerythropoietic erythropoietin receptor agonist with promising preclinical evidence for neuroprotection, neurite growth, inflammatory modulation and CNS activity. Its ability to activate EPOR-related tissue-protective pathways without producing strong erythropoiesis makes it mechanistically distinct from conventional erythropoietin. However, the evidence remains preclinical, and controlled human studies are required before its cognitive, neurological or therapeutic potential can be established.